Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Thomas O'Donnell

Vascular Surgery New York, NY Medical Doctor

NPI 1760820484 CMS profile 670209

161 Fort Washington Ave Ste 532, New York, NY 10032

Open in the dashboard

General payments

$21,587

85 records reported · program years 2020–2025

Research payments

$5,009

Paid to them · 3 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas O'Donnell of New York, NY is reported in the CMS Open Payments database as having received $21,587 across 85 general payments and $5,009 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,853 32
2025 Research $5,009 3
2024 General $1,968 18
2023 General $1,027 11
2022 General $1,614 18
2021 General $750 5
2020 General $375 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas O'Donnell
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas O'Donnell were reported at $15,853. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas O'Donnell Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $375 $348 $118–$1,110 $114
2021 $750 $471 $158–$1,421 $132
2022 $1,614 $725 $222–$2,183 $149
2023 $1,027 $836 $257–$2,440 $160
2024 $1,968 $909 $252–$2,619 $164
2025 $15,853 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Shape Memory Medical Inc. $13,629 30 payments
  2. Cook Incorporated $3,100 1 payment
  3. Terumo Medical Corporation $1,379 15 payments
  4. Silk Road Medical, Inc. $1,142 7 payments
  5. W. L. Gore & Associates, Inc. $910 14 payments
  6. Medtronic Vascular, Inc. $375 1 payment
  7. Philips Electronics North America Corporation $246 3 payments
  8. Medtronic, Inc. $216 1 payment
  9. Tactile Systems Technology Inc $175 2 payments
  10. Endologix, Inc. $128 1 payment
  11. Other $287 10 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $8,750 3 payments
  2. Food and Beverage $5,641 66 payments
  3. Travel and Lodging $3,505 13 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,100 1 payment
  5. Education $591 2 payments
Products named General payments · program years 2020–2025
  1. IMPEDE EMBOLIZATION PLUG $13,629 30 payments
  2. ENROUTE Transcarotid Neuroprotection System $1,142 7 payments
  3. ENROUTE Transcarotid Stent $1,142 7 payments
  4. R2P MISAGO $958 7 payments
  5. Azur CX Detachable $900 14 payments
  6. NAVICROSS $632 6 payments
  7. GLIDESHEATH SLENDER $597 6 payments
  8. METACROSS OTW $544 10 payments
  9. ENHANCE Transcarotid Peripheral Access Kit $520 3 payments
  10. ENROUTE .014 Guidewire $520 3 payments
  11. Other $2,731 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Shape Memory Medical Inc. $5,009 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

60

Median for Vascular Surgery: 122

Drug cost

$8,116

Median for Vascular Surgery: $14,135

Branded share of claims

80%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 28 $7,814
Cilostazol Generic 12 $197
Clopidogrel Clopidogrel Bisulfate Brand 20 $104

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$119,465

Medicare's payments for the services billed

Medicare patients

239

Average age 75

Services billed

636

109 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 53%
Ischemic heart disease 52%
Arthritis 50%
Chronic kidney disease 44%
Heart failure 37%
Atrial fibrillation 32%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record